Vapotherm (NYSE:VAPO) had its price target reduced by equities researchers at Canaccord Genuity Group from $41.00 to $35.00 in a note issued to investors on Thursday, Stock Target Advisor reports. The firm presently has a “buy” rating on the stock. Canaccord Genuity Group’s price target would indicate a potential upside of 103.61% from the company’s previous close.
VAPO has been the topic of several other reports. Zacks Investment Research cut Vapotherm from a “buy” rating to a “hold” rating in a research report on Tuesday, October 26th. Canaccord Genuity Group dropped their price objective on Vapotherm from $41.00 to $35.00 and set a “buy” rating on the stock in a research report on Thursday. Finally, BTIG Research reaffirmed a “buy” rating and set a $45.00 price objective on shares of Vapotherm in a research report on Monday, September 27th. One investment analyst has rated the stock with a hold rating and four have assigned a buy rating to the stock. According to data from MarketBeat, the company presently has an average rating of “Buy” and an average price target of $34.80.
Shares of NYSE:VAPO opened at $17.19 on Thursday. Vapotherm has a 1-year low of $16.64 and a 1-year high of $38.46. The company has a debt-to-equity ratio of 0.50, a current ratio of 3.46 and a quick ratio of 2.76. The business has a fifty day moving average price of $21.20 and a 200-day moving average price of $23.23. The company has a market capitalization of $448.19 million, a PE ratio of -7.61 and a beta of -1.33.
In other Vapotherm news, SVP Gregoire Ramade sold 2,000 shares of the firm’s stock in a transaction dated Thursday, November 4th. The stock was sold at an average price of $25.03, for a total value of $50,060.00. The sale was disclosed in a legal filing with the SEC, which is available through this hyperlink. Company insiders own 12.80% of the company’s stock.
A number of large investors have recently made changes to their positions in VAPO. Balyasny Asset Management LLC purchased a new position in shares of Vapotherm during the 3rd quarter valued at about $4,583,000. Bank of New York Mellon Corp lifted its position in shares of Vapotherm by 9.0% during the 3rd quarter. Bank of New York Mellon Corp now owns 76,328 shares of the company’s stock valued at $1,700,000 after buying an additional 6,322 shares in the last quarter. BNP Paribas Arbitrage SA lifted its position in shares of Vapotherm by 362.2% during the 3rd quarter. BNP Paribas Arbitrage SA now owns 4,160 shares of the company’s stock valued at $93,000 after buying an additional 3,260 shares in the last quarter. UBS Group AG lifted its position in shares of Vapotherm by 5.0% during the 3rd quarter. UBS Group AG now owns 25,119 shares of the company’s stock valued at $560,000 after buying an additional 1,205 shares in the last quarter. Finally, Millennium Management LLC lifted its position in shares of Vapotherm by 205.4% during the 3rd quarter. Millennium Management LLC now owns 90,637 shares of the company’s stock valued at $2,018,000 after buying an additional 60,961 shares in the last quarter. 70.41% of the stock is currently owned by institutional investors and hedge funds.
Vapotherm Company Profile
Vapotherm, Inc is a medical technology company, which engages in the development and commercialization of medical devices for patients suffering from respiratory distress. Its products include Precision Flow, Precision Flow Heliox, Oxygen Assist Module, Nitric Oxidie Disposable Patient Circuit, Tracheostomy Adapter, and Aerogen Adapter.
Featured Story: Systematic Risk
Receive News & Ratings for Vapotherm Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Vapotherm and related companies with MarketBeat.com's FREE daily email newsletter.